• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Highlights of India’s first Biotech startup Expo
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid
  • Moderna and Pfizer: Lawsuits and Charitable Giving
  • European Commission Approves Two GM Crops for Food and Feed
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Biotech News - Featured»U.S. Department of Defense Awards Moderna $1.97 Billion COVID-19 Vaccine Contract

U.S. Department of Defense Awards Moderna $1.97 Billion COVID-19 Vaccine Contract

0
By Biotech Express on January 10, 2021 Biotech News - Featured, SARS- CoV2 & COVID-19 Updates

Printed in January 2021 Issue

The U.S. United States Department of Defense (DOD) awarded Moderna a contract worth $1,966,598,000 for an additional 100 million doses of its COVID-19 vaccine. The manufacturing will be handled in Cambridge, Massachusetts and is expected to be fulfilled by June 30, 2021.

Moderna’s vaccine has been granted emergency use authorization (EUA) in the U.S. and in Canada. The EUA was granted by the FDA on December 18 for individuals 18 years of age and older. Health Canada granted authorization on December 23. The Canadian authorization came under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 and was based on a rolling review of data that started on October 12. It included data from the Phase III COVE trial of 30,000 volunteers.

Earlier in December, the Canadian government exercised its option to increase its confirmed order of the vaccine by 20 million doses, bringing the total commitment to 40 million doses.

The European Commission (EC) has secured 160 million doses of Moderna’s vaccine, although the European medicines Agency (EMA) has yet to authorize the vaccine for use in the European Union. A meeting of the EMA’s Committee for Human Medicines (CHMP) is scheduled for January 6, 2021.

The UK government has received a commitment for seven million doses of the Moderna vaccine, 40 million of the Pfizer-BioNTech vaccine, and 100 million doses of the AstraZeneca-University of Oxford vaccine. The Pfizer-BioNTech vaccine is already being distributed in the UK and the U.S. Expectations are that the AstraZeneca-Oxford vaccine will be authorized in the UK on January 4, although there is as yet no indications when or if it will be authorized in the U.S. As of this date, U.S.-based clinical trials of the AstraZeneca-Oxford vaccine have not yet been completely enrolled.

The AstraZeneca-Oxford vaccine was delayed in the U.S. after a clinical hold was placed on the trial after a UK patient suffered a severe reaction, transverse myelitis, a partial paralysis of the spine, that may have been caused by the vaccine. Although the trials restarted after a few days in the UK and other countries, it was delayed for a number of weeks while the FDA evaluated it. There have also been confounding results in the trials, with 1800 participants accidentally receiving a half-dose of the first injection and that group reporting an efficacy of 90%, compared to about 62% in the regular doses. Researchers do not yet understand the disparity.

In the U.S., Moderna has committed to 200 million doses—not including the additional 100 million for the DOD. The company reported on December 11 that the U.S. government had exercised its option to acquire an additional 100 million doses of the vaccine, bringing it up to 200 million. About 20 million are expected to be delivered by the end of this week with the rest available in the first quarter of 2021. The second half of the 200 million will be delivered in the second quarter of 2021.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Researchers who jumped into the field from distant disciplines published lower impact work, study finds

AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak

Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid

Leave A Reply Cancel Reply

Current Issue – May 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
  • Moderna and Pfizer: Lawsuits and Charitable Giving May 25, 2022
  • European Commission Approves Two GM Crops for Food and Feed May 25, 2022
  • Ayush Ministry, DBT sign MoU for cooperation on evidence-based biotech interventions in Ayush sector May 24, 2022
  • CCI, India merger approved absorption of Covidshield Technologies into Biocon Biologics May 20, 2022
  • No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible? May 19, 2022
  • Industry lobbying on WHO overshadowing public health policy, researchers suggest May 18, 2022
  • Letter: Public Health Bill to be presented in the Monsoon session 2022 is Illegal, Unconstitutional and Arbitrary: Dr Maya Valecha May 15, 2022
  • Paid publishing in science has killed peer review system, says CSIR’s ex-chief Shekhar Mande May 15, 2022
  • Bill Gates tests positive for COVID-19 even after many booster doses, mocked on twitter May 10, 2022
  • Another Ivermectin COVID-19 paper retracted May 8, 2022
  • COVID-19 spike protein paper retracted May 7, 2022
  • Killer Music? Can sound make a clot in a boy who died while dancing or it is related to COVID vaccination May 7, 2022
  • Clotting Risks Cause FDA to Restrict Use of J&J COVID Vaccine May 6, 2022
  • Department of Pharmaceuticals releases “Common Guidelines on Pharmaceutical Innovation and Entrepreneurship” for academic institutions May 6, 2022
  • No medical care for 45% of recorded deaths in 2020, highest ever in India: New data May 6, 2022
  • Indian opposition seeks higher compensation for COVID deaths after damning WHO report May 6, 2022
  • Redcliffe Lifetech raises $61 million in Series B funding May 6, 2022
  • Engineers Create an Enzyme That Breaks Down Plastic Waste in Hours, Not Decades May 5, 2022
  • Eris Lifesciences acquires 100% stake in Oaknet Healthcare for Rs 650 cr May 5, 2022
  • The Union Government has Lied to the Supreme Court in COVID Vaccines Case? May 5, 2022
  • COVID-19- vitamin D paper from India retracted by Springer Nature journal May 4, 2022
  • IISc develops 3D printed gloves for rehabilitating stroke patients May 4, 2022
  • A new wearable technology — for plants May 4, 2022
  • Sanofi India names Rodolfo Hrosz managing director effective June 1 May 4, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.